Gene therapy for ornithine transcarbamylase deficiency.
Ornithine transcarbamylase (OTC) deficiency in humans is the most common and severe inborn error of the urea cycle. Despite therapeutic advances, OTC deficiency remains without adequate treatment, hence mortality rates are high. In the two available strains of OTC-deficient murine models, spf and spfash, researchers have tried to make genetic corrections by introducing the OTC gene. Transient but complete recovery of OTC was obtained in adult spfash mice and in OTC-deficient human primary hepatocytes, using a recombinant adenoviral vector. These experiments represent a first step in the development of human gene therapy for OTC deficiency and other hepatic enzyme deficiencies.
Kiwaki
K
K
Department of Pediatrics, Kumamoto University School of Medicine, Japan.
Matsuda
I
I
D000256:Adenoviridae / Q000235:genetics; D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000235:genetics / Q000628:therapy*; D000818:Animals; D004195:Disease Models, Animal; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D009954:Ornithine Carbamoyltransferase / Q000235:genetics; D020163:Ornithine Carbamoyltransferase Deficiency Disease; D012190:Retroviridae / Q000235:genetics
D009954:Ornithine Carbamoyltransferase